Extension of SEARCH SAPPHIRE Dynamic Choice Prevention Study
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
The overall purpose of this SEARCH SAPPHIRE CAB-LA extension study is to 1) Determine if
adding the option of Cabotegravir Injectable Suspension (CAB-LA) as a prevention choice using
a patient-centered HIV prevention delivery model increases prevention coverage compared to
the standard-of-care in three ongoing randomized trials of Dynamic Choice Prevention in rural
Uganda and Kenya; and, 2) Conduct a hybrid implementation study (Primary Objective Clinical
and Secondary Objective Implementation) focusing on initial implementation of a
patient-centered model for CAB-LA using the RE-AIM evaluation framework among persons
randomized to the intervention arms.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Infectious Diseases Research Collaboration, Uganda Kenya Medical Research Institute Makerere University National Heart, Lung, and Blood Institute (NHLBI) National Institute of Allergy and Infectious Diseases (NIAID) National Institute of Mental Health (NIMH) National Institute on Alcohol Abuse and Alcoholism (NIAAA) University of California, Berkeley University of Pittsburgh ViiV Healthcare